Publication: Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings
Issued Date
2014-04-04
Resource Type
ISSN
14726963
Other identifier(s)
2-s2.0-84899585795
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
BMC Health Services Research. Vol.14, No.1 (2014)
Suggested Citation
Suvimol Niyomnaitham, Andrew Page, Adam La Caze, Karen Whitfield, Alesha J. Smith Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings. BMC Health Services Research. Vol.14, No.1 (2014). doi:10.1186/1472-6963-14-151 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/34255
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings
Other Contributor(s)
Abstract
Background: A see on cardiovascular diseases and bladder cancer. The changes to the patterns of rosiglitazone and pioglitazone utilisation in Australia following the timing of these various health authority warnings such as the Australian Therapeutic Good Administration (TGA), European Medicines Agency (EMA) press releases or U.S. Food and Drug Administration (FDA) is unknown. This study investigated the utilisation patterns of rosiglitazone and pioglitazone in Australia before and after warnings of major drug authorities. Methods. We evaluated rosiglitazone and pioglitazone dispensing using the Pharmaceutical Benefit Scheme (PBS) subsidised drug dispensing data for the Australian population from February 2004 to July 2012. The World Health Organisation Anatomic Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) system was used to compare the drug utilisation patterns following the announcements of EMA, FDA, and TGA safety warnings, which first occurred in May 2007. The DDD/1000population/day were examined in a series of time-series regression analysis with the drug safety warnings specified as interventions. Results: Rosiglitazone utilisation increased steadily from 2004 until reaching a peak at 1.96/1000population/day in January 2007. Then rosiglitazone use decreased significantly after the initial EMA press release and FDA warning on cardiovascular risk in May 2007 (with a 15.04% average monthly decline, p-value <0.001), however use did not significantly decrease after the TGA warning or subsequent EMA and FDA warnings. Pioglitazone utilisation proceeded rosiglitazone in September 2008 and remained above 1.5/1000/day during 2009-2010. However, pioglitazone utilisation has slightly declined after the FDA, EMA, and TGA warnings related to bladder cancer. Conclusions: Drug safety warnings were associated with a decrease in rosiglitazone and pioglitazone utilisation in Australia. Rosiglitazone began to decline prior to TGA warnings in December 2007, which suggests that Australian prescribers may have acted in response to scientific evidence or international safety warnings (EMA, FDA), prior to the response of the TGA. Minor effects were observed after bladder cancer warnings on pioglitazone utilisation. © 2014 Niyomnaitham et al.; licensee BioMed Central Ltd.